514 related articles for article (PubMed ID: 18685489)
1. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
2. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
3. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
Fujisawa H; Marukawa K; Hasegawa M; Tohma Y; Hayashi Y; Uchiyama N; Tachibana O; Yamashita J
J Neurosurg; 2002 Dec; 97(6):1350-5. PubMed ID: 12507133
[TBL] [Abstract][Full Text] [Related]
4. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
Schittenhelm J; Trautmann K; Tabatabai G; Hermann C; Meyermann R; Beschorner R
Mod Pathol; 2009 Dec; 22(12):1600-11. PubMed ID: 19767728
[TBL] [Abstract][Full Text] [Related]
6. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system.
Sasaki T; Lopes MB; Hankins GR; Helm GA
Acta Neuropathol; 2002 Jul; 104(1):105-9. PubMed ID: 12070671
[TBL] [Abstract][Full Text] [Related]
7. Nogo-A expression in oligodendroglial tumors.
Jung TY; Jung S; Lee KH; Cao VT; Jin SG; Moon KS; Kim IY; Kang SS; Kim HS; Lee MC
Neuropathology; 2011 Feb; 31(1):11-9. PubMed ID: 20487307
[TBL] [Abstract][Full Text] [Related]
8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value.
Schwab DE; Lepski G; Borchers C; Trautmann K; Paulsen F; Schittenhelm J
Pathol Res Pract; 2018 Jan; 214(1):15-24. PubMed ID: 29258767
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas.
Fults D; Pedone C
Neuro Oncol; 2000 Apr; 2(2):71-9. PubMed ID: 11303623
[TBL] [Abstract][Full Text] [Related]
12. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
13. MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration.
Suzuki SO; Kitai R; Llena J; Lee SC; Goldman JE; Shafit-Zagardo B
J Neuropathol Exp Neurol; 2002 May; 61(5):403-12. PubMed ID: 12025943
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
Hägerstrand D; Smits A; Eriksson A; Sigurdardottir S; Olofsson T; Hartman M; Nistér M; Kalimo H; Ostman A
Neuro Oncol; 2008 Feb; 10(1):2-9. PubMed ID: 18003890
[TBL] [Abstract][Full Text] [Related]
15. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
[TBL] [Abstract][Full Text] [Related]
16. Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells.
Blümcke I; Becker AJ; Normann S; Hans V; Riederer BM; Krajewski S; Wiestler OD; Reifenberger G
J Neuropathol Exp Neurol; 2001 Oct; 60(10):984-93. PubMed ID: 11589429
[TBL] [Abstract][Full Text] [Related]
17. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
18. Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neoplastic infiltration.
Landry CF; Verity MA; Cherman L; Kashima T; Black K; Yates A; Campagnoni AT
Cancer Res; 1997 Sep; 57(18):4098-104. PubMed ID: 9307299
[TBL] [Abstract][Full Text] [Related]
19. Identification of gliomas by morphological and immunocytochemical analysis in cell cultures.
Fazekas I; Kerekes E; Hegedús B; Nyáry I
Ideggyogy Sz; 2002 May; 55(5-6):173-9. PubMed ID: 12122877
[TBL] [Abstract][Full Text] [Related]
20. Epithelial differentiation in gliomas, meningiomas and choroid plexus papillomas.
Cruz-Sánchez FF; García-Bachs M; Rossi ML; Rodríguez-Prados S; Ferrer I; Coakham HB; Ferreres JC; Figols J; Palacin A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1992; 62(1):25-34. PubMed ID: 1352072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
